西布曲明对实验室人体进食模式中暴饮暴食、饥饿感和饱腹感的影响。
Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm.
作者信息
Mitchell James E, Gosnell Blake A, Roerig James L, de Zwaan Martina, Wonderlich Stephen A, Crosby Ross D, Burgard Melissa A, Wambach Beth N
机构信息
The Neuropsychiatric Research Institute and the University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA.
出版信息
Obes Res. 2003 May;11(5):599-602. doi: 10.1038/oby.2003.85.
OBJECTIVE
The purpose of this study was to evaluate the effects of sibutramine vs. placebo on binge-eating behavior, hunger, and satiety in patients who had problems with binge eating.
RESEARCH METHODS AND PROCEDURES
Seven adult subjects who had problems with binge eating (mean age, 42 years) were randomly assigned to receive alternating sibutramine and placebo in a double-blind placebo-controlled crossover study. This involved two 4-week dosing periods separated by a 2-week washout.
RESULTS
Subjects lost weight on sibutramine but not on placebo. There was a significant difference in the number of kilocalories consumed between the sibutramine and placebo conditions, with a significant reduction of intake during binge-eating episodes on sibutramine.
DISCUSSION
Sibutramine suppresses intake during binge-eating episodes. This effect is demonstrable in a human feeding laboratory paradigm.
目的
本研究旨在评估西布曲明与安慰剂对有暴饮暴食问题患者的暴饮暴食行为、饥饿感和饱腹感的影响。
研究方法与步骤
在一项双盲安慰剂对照交叉研究中，7名有暴饮暴食问题的成年受试者（平均年龄42岁）被随机分配接受西布曲明和安慰剂交替治疗。这包括两个为期4周的给药期，中间间隔2周的洗脱期。
结果
受试者服用西布曲明后体重减轻，而服用安慰剂后体重未减轻。西布曲明组和安慰剂组之间消耗的千卡数存在显著差异，服用西布曲明期间暴饮暴食发作时的摄入量显著减少。
讨论
西布曲明可抑制暴饮暴食发作时的摄入量。这种效果在人体进食实验室范式中得到了证实。
Zotero 插件